Innoviva Net Income/Loss 2012-2026 | INVA
Innoviva net income/loss from 2012 to 2026. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
|
Innoviva Annual Net Income/Loss (Millions of US $) |
|
|---|---|
| 2025 | $271 |
| 2024 | $23 |
| 2023 | $180 |
| 2022 | $220 |
| 2021 | $369 |
| 2020 | $294 |
| 2019 | $191 |
| 2018 | $406 |
| 2017 | $134 |
| 2016 | $60 |
| 2015 | $-19 |
| 2014 | $-168 |
| 2013 | $-171 |
| 2012 | $-19 |
| 2011 | $-115 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |